Microbial Insights, Inc.

microbe.com

Microbial Insights (MI) is a biotechnology laboratory specializing in the development and application of cutting edge molecular biological tools (MBTs) and environmental molecular diagnostics (EMDs) to describe and quantify microbial communities. Environmental Remediation: CENSUS qPCR and QuantArray analyses to quantify bacteria and functional genes involved in contaminant biodegradation including Dehalococcoides. Stable isotope probing (SIP) and Compound Specific Isotope Analysis (CSIA) to conclusively determine whether biodegradation is occurring in situ.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

TEXAS CHILDREN'S PAVILION FOR WOMEN ACQUIRES AUSTIN PERINATAL ASSOCIATES EXPANDING HOSPITAL'S MATERNAL-FETAL MEDICINE FOOTPRINT TO CENTRAL TEX

Texas Children's Hospital | May 09, 2022

news image

Texas Children's Physician Group announced today that it has completed the acquisition of Austin Perinatal Associates, a well-known private maternal-fetal medicine practice based in Austin. Located at 6500 North Mopac Expressway, the facility is the ninth community maternal-fetal medicine clinic operated by the Texas Children's Pavilion for Women and the first to offer women's services in Central Texas – bringing the hospital's well-known, top tier women'...

Read More

Research, Industry Outlook

LUMINULTRA LAUNCHES BUGCOUNT® FUEL, A REVOLUTIONARY MICROBIAL TEST FOR FUELS

PRnewswire | July 06, 2023

news image

LuminUltra today announced the launch of BugCount® Fuel, an innovative, user-friendly test kit to quickly and accurately evaluate fuels for microbial contamination which can cause significant challenges for a range of industries including aviation, marine, and fuel handling. Microbiological testing of fuel is critical for identifying and getting ahead of issues that lead to compromised performance, including clogged filters, worn injectors, fuel tank lining (pitting) corrosi...

Read More

Industrial Impact, Medical

EMULATE PUBLISHES LANDMARK STUDY VALIDATING ORGAN-ON-A-CHIP TECHNOLOGY FOR PREDICTIVE TOXICOLOGY IN PRECLINICAL DEVELOPMENT

Emulate, Inc. | December 07, 2022

news image

Emulate, Inc., the leading provider of next-generation in vitro models announced the publication of a landmark study, “Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology,” in Nature Communications Medicine demonstrating that the Emulate human Liver-Chip could improve patient safety and reduce small-molecule clinical trial failures due to liver toxicity by up to 87%. These findings conclude the single largest Organ-Chip study to date, in which...

Read More

Medical

PEPTILOGICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE CLINICAL TRIAL OF PLG0206 IN PERIPROSTHETIC JOINT INFECTION

Peptilogics | January 11, 2022

news image

Peptilogics, a biotech company that engineers peptide therapeutics to radically improve the treatment landscape for patients with life-threatening diseases, announced that the U.S. Food and Drug Administration as accepted the company's Investigational New Drug Application for PLG0206 to treat periprosthetic joint infection allowing the Phase 1b study to proceed. Peptilogics will evaluate the safety and efficacy of PLG0206 in a Phase 1b open-label, dose-escalating study i...

Read More
news image

Medical

TEXAS CHILDREN'S PAVILION FOR WOMEN ACQUIRES AUSTIN PERINATAL ASSOCIATES EXPANDING HOSPITAL'S MATERNAL-FETAL MEDICINE FOOTPRINT TO CENTRAL TEX

Texas Children's Hospital | May 09, 2022

Texas Children's Physician Group announced today that it has completed the acquisition of Austin Perinatal Associates, a well-known private maternal-fetal medicine practice based in Austin. Located at 6500 North Mopac Expressway, the facility is the ninth community maternal-fetal medicine clinic operated by the Texas Children's Pavilion for Women and the first to offer women's services in Central Texas – bringing the hospital's well-known, top tier women'...

Read More
news image

Research, Industry Outlook

LUMINULTRA LAUNCHES BUGCOUNT® FUEL, A REVOLUTIONARY MICROBIAL TEST FOR FUELS

PRnewswire | July 06, 2023

LuminUltra today announced the launch of BugCount® Fuel, an innovative, user-friendly test kit to quickly and accurately evaluate fuels for microbial contamination which can cause significant challenges for a range of industries including aviation, marine, and fuel handling. Microbiological testing of fuel is critical for identifying and getting ahead of issues that lead to compromised performance, including clogged filters, worn injectors, fuel tank lining (pitting) corrosi...

Read More
news image

Industrial Impact, Medical

EMULATE PUBLISHES LANDMARK STUDY VALIDATING ORGAN-ON-A-CHIP TECHNOLOGY FOR PREDICTIVE TOXICOLOGY IN PRECLINICAL DEVELOPMENT

Emulate, Inc. | December 07, 2022

Emulate, Inc., the leading provider of next-generation in vitro models announced the publication of a landmark study, “Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology,” in Nature Communications Medicine demonstrating that the Emulate human Liver-Chip could improve patient safety and reduce small-molecule clinical trial failures due to liver toxicity by up to 87%. These findings conclude the single largest Organ-Chip study to date, in which...

Read More
news image

Medical

PEPTILOGICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE CLINICAL TRIAL OF PLG0206 IN PERIPROSTHETIC JOINT INFECTION

Peptilogics | January 11, 2022

Peptilogics, a biotech company that engineers peptide therapeutics to radically improve the treatment landscape for patients with life-threatening diseases, announced that the U.S. Food and Drug Administration as accepted the company's Investigational New Drug Application for PLG0206 to treat periprosthetic joint infection allowing the Phase 1b study to proceed. Peptilogics will evaluate the safety and efficacy of PLG0206 in a Phase 1b open-label, dose-escalating study i...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us